XOMA, Ltd. has entered into an agreement with Taligen Therapeutics, Inc. of Aurora, CO for the development and cGMP manufacture of a novel antibody fragment for the potential treatment of inflammatory diseases. Under the agreement, XOMA will utilize its Bacterial Cell Expression technology to develop and scale-up production processes for Taligen’s FAb antibody fragment. XOMA will also manufacture quantities of the antibody fragment sufficient to support preclinical and initial clinical tri...